Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Arthritis Research & Therapy
Published in: Arthritis Research & Therapy 2/2003

01-09-2003 | Meeting abstract

Cytotoxic drugs in ocular lesions of Behçet's disease

Authors: F Davatchi, F Shahram, H Chams, A Nadji, AR Jamshidi, C Chams, M Akbarian, F Gharibdoost, M Sedigh, B Sadeghi

Published in: Arthritis Research & Therapy | Special Issue 2/2003

Login to get access

Excerpt

Cytotoxic drugs are the first line treatment for ophthalmologic manifestations of Behçet's disease (BD) despite the advent of the new biological agents. The latter are to be used in intractable inflammatory attacks as they seem to be efficient in a few case studies. Cytotoxic drugs are affordable, easy to use, effective and safe, even in long-term use. They have to be combined to steroids (0.5 mg prednisolone/kg per day as attack dose, then tapering gradually to the patient's need). All the cytotoxic drugs used were effective (ACR 1966, APLAR 2000). …
Metadata
Title
Cytotoxic drugs in ocular lesions of Behçet's disease
Authors
F Davatchi
F Shahram
H Chams
A Nadji
AR Jamshidi
C Chams
M Akbarian
F Gharibdoost
M Sedigh
B Sadeghi
Publication date
01-09-2003
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue Special Issue 2/2003
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar978

Other articles of this Special Issue 2/2003

Arthritis Research & Therapy 2/2003 Go to the issue

Meeting abstract

A review on disease activity scores in Behçet's disease (BD)

Meeting abstract

Regulation of inflammatory CD28- T-helper cells by HLA class I molecules: a new cellular model for Behçet's disease?

Meeting abstract

Viral infection of retinal pigment epithelium: a possible role for initiation of Behçet's disease

Meeting abstract

The use of interferon-alfa in Behçet's disease: review of the literature

Meeting abstract

Efficacy of recombinant human interferon-alfa2a on ocular and extra-ocular manifestations of Behçet's disease and influence on cells of the immune system: results of an open four center trial

Meeting abstract

Behçet's disease: from innate to adaptive immunity
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits